Paratek Pharms Inc Drug Patent Portfolio

Paratek Pharms Inc owns 1 orange book drug protected by 11 US patents Given below is the list of Paratek Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10383884 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) 31 Oct, 2037
Active
US10835542 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) 31 Oct, 2037
Active
US10111890 9-aminomethyl minocycline compounds and uses thereof 03 Aug, 2037
Active
US9314475 Oral and injectable formulations of tetracycline compounds 18 Mar, 2031
Active
US8383610 Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline 23 Sep, 2030
Active
US10124014 Minocycline compounds and methods of use thereof 05 Mar, 2029
Active
US9265740 Minocycline compounds and methods of use thereof 05 Mar, 2029
Active
US9724358 Minocycline compounds and methods of use thereof 05 Mar, 2029
Active
US7553828 9-aminomethyl substituted minocycline compounds 02 Jun, 2025
Active
US7326696 Amino-methyl substituted tetracycline compounds 24 Sep, 2023 Expired
US9365500 9-aminomethyl substituted minocycline compounds 29 Jun, 2021 Expired


Given below is the list of recent legal activities going on the following drug patents of Paratek Pharms Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 17 May, 2024 US10835542
Interim Patent Term Extension Granted 13 May, 2024 US7553828
Court Processing Terminated 17 Apr, 2024 US7553828
transaction for FDA Determination of Regulatory Review Period 18 Jan, 2024 US7553828
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US7553828
Payment of Maintenance Fee, 8th Year, Large Entity 19 Oct, 2023 US9314475
Payment of Maintenance Fee, 4th Year, Large Entity 20 Feb, 2023 US10383884
Interim Patent Term Extension Granted 17 Feb, 2023 US7553828
Second letter to regulating agency to determine regulatory review period 17 Feb, 2023 US7553828
Case Docketed to Examiner in GAU 05 Oct, 2022 US7553828
Payment of Maintenance Fee, 4th Year, Large Entity 13 May, 2022 US10124014
Payment of Maintenance Fee, 4th Year, Large Entity 02 May, 2022 US10111890
Payment of Maintenance Fee, 4th Year, Large Entity 08 Feb, 2021 US9724358
Payment of Maintenance Fee, 12th Year, Large Entity 30 Dec, 2020 US7553828
Recordation of Patent Grant Mailed 17 Nov, 2020 US10835542


Paratek Pharms Inc Drug Patents' Oppositions Filed in EPO

Paratek Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 28, 2021, by Lederer & Keller Patentanwälte Partnerschaft Mbb. This opposition was filed on patent number EP18158017A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18158017A May, 2021 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition


Paratek Pharms Inc's Family Patents

Paratek Pharms Inc drugs have patent protection in a total of 40 countries. It's US patent count contributes only to 21.2% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Paratek Pharms Inc Drug List

Given below is the complete list of Paratek Pharms Inc's drugs and the patents protecting them.


1. Nuzyra

Nuzyra is protected by 11 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10383884 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) 31 Oct, 2037
(13 years from now)
Active
US10835542 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) 31 Oct, 2037
(13 years from now)
Active
US10111890 9-aminomethyl minocycline compounds and uses thereof 03 Aug, 2037
(12 years from now)
Active
US9314475 Oral and injectable formulations of tetracycline compounds 18 Mar, 2031
(6 years from now)
Active
US8383610 Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline 23 Sep, 2030
(5 years from now)
Active
US10124014 Minocycline compounds and methods of use thereof 05 Mar, 2029
(4 years from now)
Active
US9265740 Minocycline compounds and methods of use thereof 05 Mar, 2029
(4 years from now)
Active
US9724358 Minocycline compounds and methods of use thereof 05 Mar, 2029
(4 years from now)
Active
US7553828 9-aminomethyl substituted minocycline compounds 02 Jun, 2025
(7 months from now)
Active
US7326696 Amino-methyl substituted tetracycline compounds 24 Sep, 2023
(1 year, 12 days ago)
Expired
US9365500 9-aminomethyl substituted minocycline compounds 29 Jun, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuzyra's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List